This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Green, J. F. Articles by Trimble, K. M. Search for Related Content PubMed PubMed Citation Articles by Green, J. F. Articles by Trimble, K. M. Social Bookmarking                         What's this?

Antisaccade and smooth pursuit eye movements in healthy subjects receiving sertraline and lorazepam

Department of Therapeutics and Pharmacology, The Queen’s University of Belfast, Belfast, UK, Jonathan.Green{at}nda.n-i.nhs.uk

David J. King

Department of Therapeutics and Pharmacology, The Queen’s University of Belfast, Belfast, UK

Karen M. Trimble

Department of Therapeutics and Pharmacology, The Queen’s University of Belfast, Belfast, UK

Patients suffering from some psychiatric and neurological disorders demonstrate abnormally high levels of saccadic distractibility when carrying out the antisaccade task. This has been particularly thoroughly demonstrated in patients with schizophrenia. A large body of evidence has been accumulated from studies of patients which suggests that such eye movement abnormalities may arise from frontal lobe dysfunction. The psychopharmacology of saccadic distractibility is less well understood, but is relevant both to interpreting patient studies and to establishing the neurological basis of their findings. Twenty healthy subjects received lorazepam 0.5 mg, 1 mg and 2 mg, sertraline 50 mg and placebo in a balanced, repeated measures study design. Antisaccade, no-saccade, visually guided saccade and smooth pursuit tasks were carried out and the effects of practice and drugs measured. Lorazepam increased direction errors in the antisaccade and no-saccade tasks in a dose-dependent manner. Sertraline had no effect on these measures. Correlation showed a statistically significant, but rather weak, association between direction errors and smooth pursuit measures. Practice was shown to have a powerful effect on antisaccade direction errors. This study supports our previous work by confirming that lorazepam reliably worsens saccadic distractibility, in contrast to other psychotropic drugs such as sertraline and chlorpromazine. Our results also suggest that other studies in this field, particularly those using parallel groups design, should take account of practice effects.

Journal of Psychopharmacology, Vol. 14, No. 1, 30-36 (2000)
DOI: 10.1177/026988110001400103


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. Lencer, A. Sprenger, M. S. H. Harris, J. L. Reilly, M. S. Keshavan, and J. A. Sweeney Effects of Second-Generation Antipsychotic Medication on Smooth Pursuit Performance in Antipsychotic-Naive Schizophrenia Arch Gen Psychiatry, October 1, 2008; 65(10): 1146 - 1154. [Abstract] [Full Text] [PDF]

				S.L. de Haas, S.J. de Visser, J.P. van der Post, M. de Smet, R.C. Schoemaker, B. Rijnbeek, A.F. Cohen, J.M. Vega, N.G.B. Agrawal, T.V. Goel, et al. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA {alpha}2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers J Psychopharmacol, June 1, 2007; 21(4): 374 - 383. [Abstract] [PDF]